GLP-1 receptor agonists are reshaping care for type 2 diabetes, obesity, chronic kidney disease, and obstructive sleep apnea, ...

Please provide your email address to receive an email when new articles are posted on . SGLT2 inhibitors were linked to lower risks for CKD and AKI but greater risks for albuminuria vs. GLP-1s. Risk ...

In a comparative study evaluating SGLT2 inhibitors and GLP-1 medications, the former drug class was associated with lower risk of chronic kidney disease and acute kidney injury. The study, published ...

As GLP‑1 medications become increasingly common for diabetes management and weight loss, questions have emerged about whether they influence the risk of developing kidney stones. Kyle Wood, M.D., MBA, ...

People with type 1 diabetes who took GLP-1 receptor agonist (GLP-1-RA) drugs for weight loss or better blood-sugar control had significantly reduced risks of major cardiovascular events and end-stage ...

A majority of GLP-1 lawsuits come from patients who allege that manufacturers have inadequately warned about severe side ...

GLP-1RA initiation in type 1 diabetes associated with lower risks of major cardiovascular events and end-stage kidney disease. Patients using GLP-1RAs more likely to achieve clinically meaningful ...

Company positions itself as the central research hub for patients, clinicians, and compounding pharmacies tracking the ...